Amendment and Response to Restriction Requirement

REMARKS

In response to the restriction requirement, Applicants hereby elect Group I, drawn to a method of treating an inflammatory-related disease, classified in class 514, subclass 886. As also required by the restriction requirement, Applicants elect, a single disclosed species, *i.e.*, a single compound structure, including side chains. In view of this requirement, Applicants elect the compound Meisoindigo for treatment of the inflammatory-related diseases.

The following claims read on the above election of species: Claims 1-3, 5, 7-20, 22, 24-30. Applicant appreciates the Examiner's acknowledgement that upon the allowance of a generic claim, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Applicants expressly reserve the right to file one or more divisional or continuing applications to protect the inventions of the non-elected group and other disclosed, but unclaimed, subject matter prior to the issuance of this application.

Respectfully submitted,

June 23, 2006 Date

codincy 3. I union

FENNEMORE CRAIG

Customer No. 27,887

602-916-5404

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this paper and any documents referred to herein are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 23, 2006.

Rebecca Camelio, IP Assistant

June 23, 2006

Date of Signature